Investigation of the enantioselectivity of acetylcholinesterase and butyrylcholinesterase upon inhibition by tacrine-iminosugar heterodimers

References

• Ramsay RR, Tipton KF. Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs. Molecules. 2017;22(7):1192.
   PubMed Web of Science ®Google Scholar
• Fokkens J, Klebe G. A simple protocol to estimate differences in protein binding affinity for enantiomers without prior resolution of racemates. Angew Chem Int Ed Engl. 2006;45(6):985–989.
   PubMed Web of Science ®Google Scholar
• Mentel M, Blankenfeldt W, Breinbauer R. The active site of an enzyme can host both enantiomers of a racemic ligand simultaneously. Angew Chem Int Ed Engl. 2009;48(48):9084–9087.
   PubMed Web of Science ®Google Scholar
• Brooks WH, Guida WC, Daniel KG. The significance of chirality in drug design and development. Curr Top Med Chem. 2011;1:760–770.
   Google Scholar
• McKinney M, Miller JH, Yamada F, Tuckmantel W, Kozikowski AP. Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur J Pharmacol. 1991;203(2):303–305.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Liang YQ, Tang XC, He XC, Bai DL. Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci Lett. 2002;317(3):143–146.
   PubMed Web of Science ®Google Scholar
• Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375–399.
   PubMed Web of Science ®Google Scholar
• Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacol Biochem Behav. 2003;75(3):675–686.
   PubMed Web of Science ®Google Scholar
• Orhan IE, Orhan G, Gurkas E. An overview on natural cholinesterase inhibitors–a multi-targeted drug class–and their mass production. Mini Rev Med Chem. 2011;11(10):836–842.
   PubMed Web of Science ®Google Scholar
• Dvir H, Jiang HL, Wong DM, Harel M, Chetrit M, He XC, Jin GY, Yu GL, Tang XC, Silman I, et al. X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement. Biochemistry. 2002;4:10810–10818.
   Google Scholar
• Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science. 1991;253(5022):872–879.
   PubMed Web of Science ®Google Scholar
• Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs. 2000;9(10):2393–2402.
   PubMed Web of Science ®Google Scholar
• Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999;463(3):321–326.
   PubMed Web of Science ®Google Scholar
• Kimura H, Kawai T, Hamashima Y, Kawashima H, Miura K, Nakaya Y, Hirasawa M, Arimitsu K, Kajimoto T, Ohmomo Y, et al. Synthesis and evaluation of (–)- and (+)-[11C]galanthamine as PET tracers for cerebral acetylcholinesterase imaging. Bioorg Med Chem. 2014;22(1):285–291.
   PubMed Web of Science ®Google Scholar
• Brossi A, Schönenberger B, Clark OE, Ray R. Inhibition of acetylcholinesterase from electric eel by (-)-and (+)-physostigmine and related compounds. FEBS Lett. 1986;201(2):190–192.
   PubMed Web of Science ®Google Scholar
• Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev. 1998;4(2):87–136.
   Google Scholar
• McNaught AD. Nomenclature of carbohydrates (IUPAC recommendations 1996). Pure Appl Chem. 1996;68(10):1919–2008.
   Web of Science ®Google Scholar
• Horne G, Wilson FX, Tinsley J, Williams DH, Storer R. Iminosugars past, present and future: medicines for tomorrow. Drug Discov Today. 2011;16(3-4):107–118.
   PubMed Web of Science ®Google Scholar
• Lillelund VH, Jensen HH, Liang X, Bols M. Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chem Rev. 2002;102(2):515–553.
   PubMed Web of Science ®Google Scholar
• Asano N, Nash RJ, Molyneux RJ, Fleet GWJ. Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron Asymmetry. 2000;11:49–58.
   Google Scholar
• Sánchez-Fernández EM, Gonçalves-Pereira R, Rísquez-Cuadro R, Plata GB, Padrón JM, García Fernández JM, Ortiz Mellet C. Influence of the configurational pattern of sp(2)-iminosugar pseudo N-, S-, O- and C-glycosides on their glycoside inhibitory and antitumor properties. Carbohydr Res. 2016;429:113–122.
   PubMed Web of Science ®Google Scholar
• Sánchez-Fernández EM, García-Hernández R, Gamarro F, Arroba AI, Aguilar-Diosdado M, Padrón JM, García Fernández JM, Ortiz Mellet C. Synthesis of sp2-iminosugar selenoglycolipids as multitarget drug candidates with antiproliferative, leishmanicidal and anti-inflammatory properties. Molecules. 2021;26(24):7501.
   PubMed Web of Science ®Google Scholar
• Sugimoto S, Nakajima H, Kosaka K, Hosoi H. Review: miglitol has potential as a therapeutic drug against obesity. Nutr Metab. 2015;12:51.
   Google Scholar
• Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. IJMS. 2017;18(2):441.
   Google Scholar
• Sunder-Plassmann G, Schiffmann R, Nicholls K. Migalastat for the treatment of Fabry disease. Expert Opin Orphan Drugs. 2018;6:303–309.
   Web of Science ®Google Scholar
• Noel A, Ingrand S, Barrier L. Anti-amyloidogenic effects of glycosphingolipid synthesis inhibitors occur independently of ganglioside alterations. Mol Cell Neurosci. 2016;75:63–70.
   PubMed Web of Science ®Google Scholar
• Macdonald IR, Martin E, Rosenberry TL, Darvesh S. Probing the peripheral site of human butyrylcholinesterase. Biochemistry. 2012;51(36):7046–7053.
   PubMed Web of Science ®Google Scholar
• Gloster TM, Meloncelli P, Stick RV, Zechel D, Vasella A, Davies GJ. Glycosidase inhibition: an assessment of the binding of 18 putative transition-state mimics. J Am Chem Soc. 2007;129(8):2345–2354.
   PubMed Web of Science ®Google Scholar
• Decroocq C, Stauffert F, Pamlard O, Oulaïdi F, Gallienne E, Martin OR, Guillou C, Compain P. Iminosugars as a new class of cholinesterase inhibitors. Bioorg Med Chem Lett. 2015;25(4):830–833.
   PubMed Web of Science ®Google Scholar
• Olsen JI, Plata GB, Padrón JM, López Ó, Bols M, Fernández-Bolaños JG. Selenoureido-iminosugars: a new family of multitarget drugs. Eur J Med Chem. 2016;123:155–160.
   PubMed Web of Science ®Google Scholar
• Ahuja-Casarín AI, Merino-Montiel P, Vega-Baez JL, Montiel-Smith S, Fernandes MX, Lagunes I, Maya I, Padrón JM, López Ó, Fernández-Bolaños JG. Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors. J Enzyme Inhib Med Chem. 2021;36(1):138–146.
   PubMed Web of Science ®Google Scholar
• de Santana QLO, Santos Evangelista TC, Imhof P, Baptista Ferreira S, Fernández-Bolaños JG, Sydnes MO, Lopéz Ó, Lindbäck E. Tacrine-sugar mimetic conjugates as enhanced cholinesterase inhibitors. Org Biomol Chem. 2021;19(10):2322–2337.
   PubMed Web of Science ®Google Scholar
• Santos Evangelista TC, López Ó, Puerta A, Fernandes MX, Baptista Ferreira S, Padrón JM, Fernández-Bolaños JG, Sydnes MO, Lindbäck E. A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE). J Enzyme Inhib Med Chem. 2022;37(1):2395–2402.
   PubMed Web of Science ®Google Scholar
• Janockova J, Korabecny J, Plsikova J, Babkova K, Konkolova E, Kucerova D, Vargova J, Koval J, Jendzelovsky R, Fedorocko P, et al. In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers. J Enzyme Inhib Med Chem. 2019;34(1):877–897.
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Moutayakine A, Marques C, López Ó, Bagetta D, Leitzbach L, Hagenow S, Carreiro EP, Stark H, Alcaro S, Fernández-Bolaños JG, et al. Evaluation of chromane derivatives: promising privileged scaffolds for lead discovery within Alzheimer’s disease. Bioorg Med Chem. 2022;68:116807.
   PubMed Web of Science ®Google Scholar
• Lagunes I, Martín-Batista E, Silveira-Dorta G, Fernandes MX, Padrón JM. Differential mechanism of action of the CK1ε inhibitor GSD0054. J Mol Clin Med. 2018;1:77–84.
   Google Scholar
• Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem. 2012;55(22):10282–10286.
   PubMed Web of Science ®Google Scholar
• Brazzolotto X, Wandhammer M, Ronco C, Trovaslet M, Jean L, Lockridge O, Renard PY, Nachon F. Human butyrylcholinesterase produced in insect cells: huprine-based affinity purification and crystal structure. FEBS J. 2012;279(16):2905–2916.
   PubMed Web of Science ®Google Scholar
• Santos Evangelista TC, Lopéz Ó, Sydnes MO, Fernández-Bolaños JG, Baptista Ferreira S, Emil Lindbäck E. Bicyclic 1-azafagomine derivatives: synthesis and glycosidase inhibitory testing. Synthesis. 2019;51(21):4066–4077.
   Web of Science ®Google Scholar
• Desvergnes S, Py S, Vallée Y. Total synthesis of (+)-hyacinthacine A2 based on SmI2-induced nitrone umpolung. J Org Chem. 2005;70(4):1459–1462.
   PubMed Web of Science ®Google Scholar
• Carmona AT, Whigtman RH, Robina I, Vogel P. Synthesis and glycosidase inhibitory activity of 7-deoxycasuarine. HCA. 2003;86(9):3066–3073.
   Web of Science ®Google Scholar
• Cardona F, Faggi E, Liguori F, Cacciarini M, Goti A. Total syntheses of hyacinthacine A2 and 7-deoxycasuarine by cycloaddition to a carbohydrate derived nitrone. Tetrahedron Lett. 2003;44(11):2315–2318.
   Web of Science ®Google Scholar
• D'Adamio G, Matassini C, Parmeggiani C, Catarzi S, Morrone A, Goti A, Paoli P, Cardona F. Evidence for a multivalent effect in inhibition of sulfatases involved in lysosomal storage disorders (LSDs). RSC Adv. 2016;6(69):64847–64851.
   Web of Science ®Google Scholar
• Breugst M, Reissig HU. The Huisgen reaction: milestones of the 1,3-dipolar cycloaddition. Angew Chem Int Ed Engl. 2020;59(30):12293–12307.
   PubMed Web of Science ®Google Scholar
• Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, et al. Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. Eur J Med Chem. 2019;168:58–77.
   PubMed Web of Science ®Google Scholar
• Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J. 1974;137(1):143–144.
   PubMed Web of Science ®Google Scholar
• Rosenberry TL, Brazzolotto X, Macdonald IR, Wandhammer M, Trovaslet-Leroy M, Darvesh S, Nachon F. Comparison of the binding of reversible inhibitors to human butyrylcholinesterase and acetylcholinesterase: a crystallographic, kinetic and calorimetric study. Molecules. 2017;22(12):2098.
   PubMed Web of Science ®Google Scholar
• Radić Z, Pickering NA, Vellom DC, Camp S, Taylor P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry. 1993;32(45):12074–12084.
   PubMed Web of Science ®Google Scholar
• Barak D, Kronman C, Ordentlich A, Ariel N, Bromberg A, Marcus D, Lazar A, Velan B, Shafferman A. Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem. 1994;269(9):6296–6305.
   PubMed Web of Science ®Google Scholar
• Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci U S A. 1993;90(19):9031–9035.
   PubMed Web of Science ®Google Scholar
• Holdgate G, Meek T, Grimley R. Mechanistic enzymology in drug discovery: a fresh perspective. Nat Rev Drug Discov. 2018;17(2):115–132.
   PubMed Web of Science ®Google Scholar